文献速递鼻科小儿耳鼻咽喉

双倍剂量鼻用糖皮质激素治疗变应性鼻炎的系统评价与荟萃分析

Effects of double-dose intranasal corticosteroid for allergic rhinitis: a systematic review and meta-analysis.
PubMed 文献 · Int Forum Allergy Rhinol · 2018-09-04

成人患者双倍剂量在鼻部总分和眼部总分上均优于标准剂量,而儿童患者鼻部总分两组无差异,两组不良事件无差异。

要点

  • 成人变应性鼻炎双倍剂量鼻用糖皮质激素在鼻部和眼部症状上优于标准剂量
  • 儿童患者双倍剂量与标准剂量在鼻部症状总分上无差异
  • 两组不良事件无差异

核心结论

  • 成人变应性鼻炎患者双倍剂量鼻用糖皮质激素较标准剂量能更好改善鼻部和眼部症状,但儿童患者未见此获益,两组不良事件无差异。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE和EMBASE,纳入比较双倍剂量与标准剂量鼻用糖皮质激素治疗变应性鼻炎的随机对照试验。

主要发现

  • 成人患者双倍剂量组鼻部症状总分改善优于标准剂量组(SMD -0.25;95%CI -0.41至-0.08;4项研究;568例患者)。
  • 成人患者双倍剂量组眼部症状总分改善优于标准剂量组(SMD -0.27;95%CI -0.52至-0.03;1项研究;259例患者)。
  • 儿童患者双倍剂量组与标准剂量组鼻部症状总分无差异(SMD -0.16;95%CI -0.40至0.07;3项研究;801例患者)。
  • 儿童患者眼部症状评分数据不足,未能进行荟萃分析。
  • 两组不良事件无差异。

关键数值与推荐

  • 成人鼻部症状总分:SMD -0.25(95%CI -0.41至-0.08;4项研究;568例患者)。
  • 成人眼部症状总分:SMD -0.27(95%CI -0.52至-0.03;1项研究;259例患者)。
  • 儿童鼻部症状总分:SMD -0.16(95%CI -0.40至0.07;3项研究;801例患者)。

临床怎么用

  • 成人变应性鼻炎标准剂量鼻用糖皮质激素控制不佳时,可考虑双倍剂量以改善鼻部和眼部症状。
  • 儿童变应性鼻炎不建议常规使用双倍剂量鼻用糖皮质激素,因未见优于标准剂量的证据。
  • 双倍剂量与标准剂量不良事件无差异,但仍需关注个体化用药。

局限性

  • 儿童患者眼部症状评分数据不足,无法进行荟萃分析。
  • 成人眼部症状分析仅基于1项研究259例患者,证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: When a standard dose of intranasal corticosteroid (INCS) fails to control symptoms of allergic rhinitis (AR), a double dose of INCS is optional. This systematic review aimed to assess the effects of double-dose INCS. METHODS: Literature searches were performed using MEDLINE and EMBASE. Randomized controlled trials that studied the effects of double-dose INCS vs standard-dose INCS for treating patients with AR were included. Data from the included studies were extracted and collected for meta-analyses. The outcomes were nasal symptoms, ocular symptoms, and adverse events. RESULTS: Twelve studies (4166 patients) met the inclusion criteria. There were 5 pediatric studies (1868 patients), 5 adult studies (1414 patients), and 2 studies with mixed populations (884 patients). The meta-analysis results in adult patients favored the effects of double-dose INCS on: total nasal symptom score (standardized mean difference [SMD] -0.25; 95% confidence interval [CI], -0.41 to -0.08; 4 studies; 568 patients) and total ocular symptom score (SMD -0.27; 95% CI, -0.52 to -0.03; 1 study; 259 patients). The meta-analysis results in pediatric patients did not show the difference between groups on total nasal symptom score (SMD -0.16; 95% CI, -0.40 to 0.07; 3 studies; 801 patients). The meta-analysis of ocular symptom score in pediatric patients had insufficient data. There were no differences between groups on adverse events. CONCLUSION: Double-dose INCS showed better improvement in nasal and ocular symptoms in adult patients with AR when compared to the standard dose. These beneficial effects were not seen in the pediatric population. Adverse events between groups were not different.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Khattiyawittayakun L, Seresirikachorn K, Chitsuthipakorn W, et al. Effects of double-dose intranasal corticosteroid for allergic rhinitis: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2018. PMID: 30179317. doi:10.1002/alr.22204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。